BioReagent 级 ，适用于对基线干扰要求严格的色谱和分析工作流程。
2-8°C储存。低温运输 。请查阅批次 COA 获取详细规格。
SDS、COA、产品数据表及规格说明书均可下载。可通过批号查询获取批次 COA。
在色谱分析、有机合成和交叉偶联反应领域已被 0 篇同行评审文献引用。
Durvalumab是一种用于治疗各种类型癌症的抗癌药物。它是一种人免疫球蛋白G1κ（IgG1κ）单克隆抗体，可阻断程序性细胞死亡配体1（PD-L1）的相互作用。 Durvalumab是一种免疫检查点抑制剂药物。它于 2017 年 5 月在美国获得批准用于医疗用途，并于 2018 年 9 月在欧盟获得批准。美国食品药品监督管理局 （FDA） 批准 durvalumab 用于某些类型的膀胱癌、肺癌和胆道癌。 本试剂盒采用间接法酶联免疫吸附试验（ELISA）。往预先包被有人PD-L1抗原的微孔中，依次加入样本、标准品、HRP标记的二抗，中间经过温育和洗涤，用底物TMB显色，TMB在过氧化物酶(HRP)的催化下转化成蓝色，并在酸的作用下转化成最终的黄色。颜色的深浅和样本中的度伐利尤单抗(Durvalumab)呈正相关。用酶标仪在450nm波长下测定吸光度（OD值），计算样本浓度。
This kit employs the indirect enzyme-linked immunosorbent assay (ELISA) principle. Microplate wells are pre-coated with Human PD-L1 antigen. The sample or standard is first added to the wells, followed by an HRP (horseradish peroxidase)-labeled secondary antibody. The procedure involves incubation and wash steps between each addition. TMB substrate is then added for color development. Under the catalysis of the peroxidase (HRP), TMB is converted into a blue product, which subsequently turns into a final stable yellow color upon the addition of an acid stop solution. The intensity of the yellow color is directly proportional to the concentration of Durvalumab in the sample. The optical density (OD) is measured at a wavelength of 450 nm using a microplate reader, and the concentration of the target analyte in the sample is calculated based on the standard curve.
危险品化学品经营许可证（带存储）